Emily Bourne
Women's Health · Port Charlotte, FLNPI 1326616574
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,886 and has fallen 81.9% since, to $342 in 2025. Among women's health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $47.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$554
- Astellas Pharma US Inc$450
- AbbVie$408
- Otsuka America Pharmaceutical, Inc.$382
- Bayer$346
- Amgen$266
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,43296%
- Education$1854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 6 | $554 |
| Astellas Pharma US Inc | 11 | $450 |
| AbbVie | 11 | $408 |
| Otsuka America Pharmaceutical, Inc. | 4 | $382 |
| Bayer | 7 | $346 |
| Amgen | 6 | $266 |
| Novo Nordisk | 6 | $226 |
| Lilly USA, LLC | 2 | $219 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $170 |
| GSK | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| AstraZeneca | 3 | $125 |
| Idorsia Pharmaceuticals US Inc | 1 | $124 |
| Biosense Webster, Inc. | 1 | $108 |
| Dexcom, Inc. | 1 | $100 |
| Relievant Medsystems, Inc. | 1 | $99 |
| Exeltis, USA Inc. | 5 | $93 |
| Pfizer | 5 | $87 |
| Eisai Inc. | 1 | $86 |
| Xeris Pharmaceuticals, Inc. | 1 | $84 |
| Johnson & Johnson | 2 | $83 |
| GRT US Holding, Inc. | 2 | $45 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Axonics, Inc. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Avion Pharmaceuticals | 2 | $31 |
| Exact Sciences | 1 | $28 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Mayne Pharma Commercial LLC | 1 | $22 |
| Organon | 1 | $20 |
| KCI USA, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Almatica Pharma LLC | 1 | $19 |
| Corcept Therapeutics | 1 | $15 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,617 in reported general payments places this provider in the 95th percentile of 308 women's health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 45 | $44,330 |
| MyrbetriqMirabegron | 28 | $18,660 |
| Estradiol | 81 | $4,242 |
| Estradiol (Twice Weekly)Estradiol | 19 | $1,272 |
| Methenamine Hippurate | 19 | $1,184 |
| Clobetasol Propionate | 45 | $1,040 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 56 | $837 |
| ValacyclovirValacyclovir Hcl | 28 | $588 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 26 | $483 |
| ProgesteroneProgesterone, Micronized | 11 | $443 |
| Cephalexin | 53 | $299 |
| Levofloxacin | 11 | $108 |
| Ciprofloxacin Hcl | 17 | $75 |
| Fluconazole | 29 | $67 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $31 | $44,33045 claims |
| Astellas Pharma US IncMyrbetriq | $450 | $18,66028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 women's health providers in Florida.
Other women's health in Port Charlotte
- Nancy GalyonJupiter$146K
- Nicole NeidhartJacksonville$23K
- Miok RayTampa$11K
- Michelle McCloskyMiami Beach$11K
- Dalya YebraMiami$8K
- Martha PereiraMiami$7K
- Stacey HallJacksonville$7K
- Princess LockKissimmee$5K
- Karen CorkeryTampa$4K
- Gretchen SciarrinoSarasota$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.